Yahoo
NasdaqCM - Delayed Quote USD

Curanex Pharmaceuticals Inc (CURX)

6.21 +0.43 (+7.44%)
As of November 6 at 4:00:00 PM EST. Market Open.
Chart Range Bar
Loading chart for CURX
  • Previous Close 5.78
  • Open 6.31
  • Bid 5.08 x 1300
  • Ask 5.32 x 1200
  • Day's Range 6.13 - 6.31
  • 52 Week Range 3.58 - 13.34
  • Volume 4
  • Avg. Volume 21,893
  • Market Cap (intraday) 9.739M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -7.80
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

www.curanexpharma.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CURX
6.19%
S&P 500 (^GSPC)
8.98%

1-Year Return

CURX
49.92%
S&P 500 (^GSPC)
10.87%

3-Year Return

CURX
91.83%
S&P 500 (^GSPC)
71.60%

5-Year Return

CURX
91.83%
S&P 500 (^GSPC)
59.23%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -225.06%

  • Return on Equity (ttm)

    -411.08%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.47M

  • Diluted EPS (ttm)

    -7.80

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.94M

  • Total Debt/Equity (mrq)

    5.77%

  • Levered Free Cash Flow (ttm)

    -7.71M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: